Avalo Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c) Director and Officer Trading Plans and Arrangements
During the three months ended June 30, 2026, the following directors and executive officers hadadopted, modified orterminated contracts, instructions or written plans for purchase or sale of our securities as follows:
| Name and Title | Type of Trading Arrangement | Action Taken (Date of Action) | Duration or End Date | Aggregate Numbers of Securities to be Sold(1) | Description of Trading Arrangement |
|---|---|---|---|---|---|
| Garry Neil, M.D., Chief Executive Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (May 28, 2026) | May 31, 2027 | 227,080 | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Christopher Sullivan, Chief Financial Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Modification (May 18, 2026) | May 31, 2027 | 149,786(2) | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Paul Varki, Chief Legal Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Termination (May 13, 2026) | (3) | 92,771 | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| (1) | Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the trading plans. |
| (2) | These shares reflect the aggregate maximum of shares underlying vested stock options and RSUs, including 24,200 RSUs that are expected to vest during the term of the trading plan prior to expected share withholding or sell-to-cover to satisfy tax withholding obligations associated with the expected RSU vest. |
| (3) | The arrangement was originally scheduled to remain in effect through June 30, 2026 and was terminated on May 13, 2026, effective immediately. |
Other than as disclosed above, none of our directors or executive officers adopted, modified or terminated any Rule 10b5-1(c) trading arrangements or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.